TD Cowen Initiates Coverage On Adarx Pharmaceuticals with Buy Rating

TD Cowen analyst Tyler Van Buren has initiated coverage on Adarx Pharmaceuticals (NASDAQ: ADRX) with a Buy rating. This marks a positive outlook for the company in the market.